A Phase 2, Multicenter, Open-label Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Subjects With HER2+ AR+ Metastatic or Locally Advanced Breast Cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 09 Nov 2017
At a glance
- Drugs Enzalutamide (Primary) ; Trastuzumab (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 31 Oct 2017 Planned End Date changed from 1 Dec 2017 to 1 Jun 2018.
- 19 Jun 2017 Planned End Date changed from 1 Nov 2017 to 1 Dec 2017.
- 21 Apr 2017 This trial has been completed in Spain.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History